Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endologix Stung By Double-Whammy Suspensions

Executive Summary

The specialist in stent grafts for abdominal aortic aneurysms, Endologix, has suspended shipments of its AFX AAA repair system after discovering that a manufacturing issue was causing damage to some devices. This is the second knock-back the company's biggest seller has had in as many weeks, following a CE-mark suspension earlier this month.

You may also be interested in...

Endologix Looks To COO For New Leadership And Business Turnaround

Endovascular aortic repair specialist Endologix has promoted its COO John Onopchenko to the role of chief executive. He succeeds John McDermott, who stepped down as CEO in February following a couple of challenging years for the company.

Endologix Lifts Hold On Shipments Of AAA Devices

The Dec. 29 announcement relating to non-EU shipments of AFX and some AFX2 AAA repair devices came two days after the company said it suspended shipments of its flagship system because a manufacturing issue was causing damage to some devices. The release of the hold allowed the company to end a difficult month on a positive note. Endologix announced the suspension of the CE mark for AFX and AFX2 in Europe earlier in December.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts